

Scopa James Paul  
Form 4  
March 13, 2013

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
MPM BioVentures IV QP LP

(Last) (First) (Middle)

C/O MPM ASSET  
MANAGEMENT, 200  
CLARENDON STREET, 54TH  
FLOOR

(Street)

BOSTON, MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading  
Symbol  
Pacira Pharmaceuticals, Inc. [PCRX]

3. Date of Earliest Transaction  
(Month/Day/Year)  
03/11/2013

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_ 10% Owner  
\_\_\_\_ Officer (give title \_\_\_\_X\_\_\_\_ Other (specify  
below) below)  
Former 10% Owner

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
\_\_\_\_ Form filed by One Reporting Person  
\_X\_ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of<br>Security<br>(Instr. 3) | 2. Transaction Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3. Transaction<br>Code<br>(Instr. 8) | 4. Securities Acquired (A)<br>or Disposed of (D)<br>(Instr. 3, 4 and 5) | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 3 and 4) | 6. Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I)<br>(Instr. 4) | 7. Nature of<br>Ownership<br>(Instr. 4) |   |                        |
|---------------------------------------|---|---|--------------------------------------|---|--|---|---|---|------------------------|
|                                       |   |   | Code                                 | V   | Amount<br>(A)<br>or<br>(D)   | Price   |   |   |                        |
| Common<br>Stock                       | 03/11/2013                              |   | S                                    |   | 500,000<br>(1)   | \$<br>27.86   | 2,790,479                               | I | See<br>Footnote<br>(2) |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form  
displays a currently valid OMB control  
number.**

SEC 1474  
(9-02)

## Edgar Filing: Scopa James Paul - Form 4

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2. Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4. Transaction<br>Code<br>(Instr. 8) | 5. Number<br>of<br>Derivative<br>Securities<br>Acquired<br>(A) or<br>Disposed<br>of (D)<br>(Instr. 3,<br>4, and 5) | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) | 7. Title and<br>Amount of<br>Underlying<br>Securities<br>(Instr. 3 and 4) | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Nu<br>Deriv<br>Secur<br>Benef<br>Own<br>Follo<br>Repo<br>Trans<br>(Instr |
|---|--|---|---|--------------------------------------|--|--|---|---|---|
|   |  |   |   | Code                                 | V (A) (D)  | Date<br>Exercisable  | Expiration<br>Date  | Title   | Amount<br>or<br>Number<br>of<br>Shares                                      |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships                    |
|---|----------------------------------|
|   | Director 10% Owner Officer Other |
| MPM BioVentures IV QP LP<br>C/O MPM ASSET MANAGEMENT<br>200 CLARENDON STREET, 54TH FLOOR<br>BOSTON, MA 02116                      | Former 10% Owner                 |
| Scopa James Paul<br>C/O MPM ASSET MANAGEMENT<br>601 GATEWAY BLVD., SUITE 350<br>SOUTH SAN FRANCISCO, CA 94080                     | Former 10% Owner                 |
| MPM BioVentures IV GP LLC<br>C/O MPM ASSET MANAGEMENT<br>200 CLARENDON STREET, 54TH FLOOR<br>BOSTON, MA 02116                     | Former 10% Owner                 |
| MPM BioVentures IV LLC<br>C/O MPM ASSET MANAGEMENT<br>200 CLARENDON STREET, 54TH FLOOR<br>BOSTON, MA 02116                        | Former 10% Owner                 |
| MPM Asset Management Investors BV4 LLC<br>C/O MPM ASSET MANAGEMENT<br>200 CLARENDON STREET, 54TH FLOOR<br>BOSTON, MA 02116        | Former 10% Owner                 |
| MPM BioVentures IV GmbH & Co. Beteiligungs KG<br>C/O MPM ASSET MANAGEMENT<br>200 CLARENDON STREET, 54TH FLOOR<br>BOSTON, MA 02116 | Former 10% Owner                 |

Foley Todd  
C/O MPM ASSET MANAGEMENT  
200 CLARENDON STREET, 54TH FLOOR  
BOSTON, MA 02116

Former 10% Owner

Vander Vort John  
C/O MPM ASSET MANAGEMENT  
200 CLARENDON STREET, 54TH FLOOR  
BOSTON, MA 02116

Former 10% Owner

## Signatures

By Vaughn Kailian, member of MPM BioVentures IV LLC, the managing member of MPM BioVentures IV GP LLC, the general partner of MPM BioVentures IV-QP, L.P. /s/ Vaughn Kailian

03/13/2013

\_\_Signature of Reporting Person

Date

/s/ James Paul Scopa

03/13/2013

\_\_Signature of Reporting Person

Date

By Vaughn Kailian, member of MPM BioVentures IV LLC, the managing member of MPM BioVentures IV GP LLC /s/ Vaughn Kailian

03/13/2013

\_\_Signature of Reporting Person

Date

By Vaughn Kailian, member of MPM BioVentures IV LLC /s/ Vaughn Kailian

03/13/2013

\_\_Signature of Reporting Person

Date

By Vaughn Kailian, member of MPM BioVentures IV LLC, the manager of MPM Asset Management Investors BV4 LLC /s/ Vaughn Kailian

03/13/2013

\_\_Signature of Reporting Person

Date

By Vaughn Kailian, member of MPM BioVentures IV LLC, the managing member of MPM BioVentures IV GP LLC, the managing limited partner of MPM BioVentures IV GmbH & Co. Beteiligungs KG /s/ Vaughn Kailian

03/13/2013

\_\_Signature of Reporting Person

Date

/s/ Todd Foley

03/13/2013

\_\_Signature of Reporting Person

Date

/s/ John Vander Vort

03/13/2013

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The shares were sold as follows: 468,621 by MPM BioVentures IV-QP, L.P. ("BV IV QP"), 18,054 by MPM BioVentures IV GmbH & Co. Beteiligungs KG ("BV IV KG") and 13,325 by MPM Asset Management Investors BV4 LLC ("AM BV4"). MPM BioVentures IV (1) GP LLC and MPM BioVentures IV LLC ("BV LLC") are the direct and indirect general partners of BV IV QP and BV IV KG and BV LLC is the manager of AM BV4. Vaughn M. Kailian, Ansbert Gadicke, Luke Evnin, James Paul Scopa, Todd Foley and John Vander Vort are the members of BV LLC.

## Edgar Filing: Scopa James Paul - Form 4

- (2) The shares are held as follows: 2,615,352 by BV IV QP, 100,758 by BV IV KG and 74,369 by AM BV4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his, her or its respective pecuniary interest therein.

### Remarks:

See Form 4 for Vaughn M. Kailian for additional members of this joint filing.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.